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Vasomotor hot flushes are complained of by approximately three out of four 
postmenopausal women, but their frequency and severity show great individual variation. 
Estrogen  withdrawal  is  a  key  factor  of  hot  flushes,  but  the  autonomic  nervous  system,  
regulating cardiovascular function, may also be involved. Hot flushes have been present in 
women  attending  observational  studies,  but  they  have  been  absent  (or  very  mild)  in  
randomized trials. Therefore, if hot flushes are a factor connected with vascular health, they 
could perhaps be one explanation for the divergence of cardiovascular data in observational 
versus randomized studies. 
 
The present study was designed to determine the possible impact of vasomotor symptoms 
on vascular health. One hundred and fifty healthy, recently postmenopausal women 
showing a large variation in hot flushes were studied in regard to cardiovascular health by 
way of pulse wave analysis, ambulatory blood pressure and several biochemical vascular 
markers. In addition, the responses of these variables to hormone therapy were studied. The 
severity of hot flushes was assessed by using a two-week hot flush diary.  
 
After the nitroglycerin challenge in pulse wave analysis, the time to the onset of the 
reflected wave (dependent on pulse wave velocity) was 9.2% shorter (p=0.014), and the time 
to the first systolic peak (dependent on the rapid phase of ventricular ejection) was 12.3% 
shorter (p=0.025) in asymptomatic women compared with women with severe hot flushes. 
This can be seen as evidence of vasodilatory reactivity associated with severe hot flushes, 
and  thus,  as  a  hot  flush-related  vascular  benefit.  Severe  night-time  hot  flushes  were  
accompanied by transient increases in ambulatory systolic (4.1±10.5 mmHg, p=0.061) and 
diastolic (3.1±6.8 mmHg, p=0.032) blood pressure and heart rate (3.0±7.2 beats/minute, 
p=0.043), but the diurnal blood pressure profiles showed no significant difference between 
women  without  and  with  hot  flushes  of  different  severity.  Vascular  biomarkers  were  
unaffected by hot flushes.  
 
In the 6-month hormone therapy trial the women were classified as having either tolerable 
(≤3 mild episodes/day, not likely to initiate hormone therapy in routine clinical practice) or 
intolerable (≥7 moderate/severe episodes/day, likely to initiate hormone therapy) hot 
flushes. These groups were treated in a randomized order with transdermal estradiol 
hemihydrate gel (1 mg/day), oral estradiol valerate (2 mg/day) alone or in combination with 






In women with tolerable hot flushes, oral estradiol led to decreases in the time to the first 
systolic peak (13.2%, p=0.028) and the time to the reflected wave (8.4%, p=0.018) after the 
nitroglycerin challenge. This potentially unfavorable vasoconstrictive effect was not seen in 
women with intolerable hot flushes or with the other treatment regimens. Additionally, 24-
hour systolic (3.7±1.2 mmHg, p=0.010) and diastolic (1.8±0.8 mmHg, p=0.003) blood 
pressures rose in women with tolerable hot flushes receiving oral estradiol, whereas 
decreases (-1.2±1.2 mmHg and -2.1±0.8 mmHg, respectively) were detected in women with 
intolerable hot flushes. Daytime systolic and diastolic blood pressures also increased 
(3.0±1.3 mmHg, p=0.017 and 1.8±0.9 mmHg, p=0.003, respectively) in women with 
tolerable hot flushes with oral estradiol treatment, but the same therapy led to falls (-1.9±1.3 
mmHg and 2.4±0.9 mmHg, respectively) in women with intolerable hot flushes. No such 
effects were observed as regards transdermal estradiol or oral estradiol accompanied by 
medroxyprogesterone acetate. The responses of lipids, lipoproteins, C-reactive protein and 
sex hormone-binding globulin to hormone therapy showed no association with hot flush 
status.  
 
In  conclusion,  hot  flushes  may  be  associated  with  an  increased  vasodilatory,  and  thus  a  
beneficial vascular status. Furthermore, oral estradiol leads to vasoconstrictive changes, and 
thus to possible vascular harm, but only in women whose hot flushes are so mild that they 
would probably not lead to the initiation of hormone therapy in clinical practice. Such 
potential vascular harm of hormone therapy was not seen in women with intolerable hot 
flushes, or with the other treatment regimens.  
 
Taken as  a  whole,  hot  flush  status  contributes  to  cardiovascular  health  before  and during  
hormone therapy. Severe hot flushes associate with enhanced vascular reactivity. Potentially 
unfavorable vascular effects of oral hormone therapy are seen mainly in women without 
troublesome hot flushes. Thus, if estrogen is prescribed for indications other than for the 
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Hormone therapy (HT) has long been used for the treatment of menopausal symptoms, 
such as hot flushes. Results from an abundance of observational studies showed a 30–50% 
reduction in the risk of cardiovascular disease (CVD) in current users of HT. Thus, over a 
decade ago HT was commonly recommended for the prevention of CVD (Mikkola and 
Clarkson 2002, Mikkola and Ylikorkala 2005). However, results from randomized, placebo-
controlled trials, such as the Heart and Estrogen/progestin Replacement Study  (HERS) 
(Hulley et al. 1998, Grady et al. 2002) and the Women’s Health Initiative (WHI) (Rossouw et al. 
2002, Manson et al. 2003)  indicated an increased risk of CVD in HT users (Hodis and Mack 
2008).  These  findings,  widely  debated  in  both  the  medical  and  lay  press,  led  to  major  
changes in clinical practice when millions of women around the world discontinued use of 
HT (Utian 2007).   
 
Numerous plausible explanations for these divergent data have been suggested, including 
the  “healthy  woman”  bias  in  observational  studies,  and  possible  differences  in  treatment  
regimens and study populations between observational and randomized studies (Mikkola 
and Clarkson 2002, Grodstein  et  al.  2003).  The  presence  of  vasomotor  hot  flushes  has  also  
emerged as one possible explanation (Mikkola and Ylikorkala 2005, van der Schouw and Grobbee 
2005). Hypoestrogenism certainly contributes to the onset of hot flushes, but the autonomic 
nervous system, which regulates the vascular bed, among  other things, may be involved 
(Freedman 1998). In clinical practice women with severe hot flushes seek HT treatment, 
which  is  the  most  effective  treatment  against  for  them,  and thus,  such  women have  been 
included in HT groups in observational studies.  In contrast,  hot flushes have been absent,  
or very mild, in women taking part in randomized clinical trials, where women with severe 
hot flushes have been excluded from participation.  
 
Differences also exist in treatment regimens, e.g. in United States the use of conjugated 
equine estrogens (CEE) is favored, whereas in Europe estradiol-based regimens dominate 
(Mikkola and Clarkson 2002, Grodstein et al. 2003, van der Schouw and Grobbee 2005).  It  is also 
possible that progestagens possess direct or indirect vascular effects (Koh and Sakuma 2004). 
In this regard medroxyprogesterone acetate (MPA) has been most widely discussed, because 
MPA as a continuous complement of CEE was present in both the HERS and WHI trials. 
However,  it  is  still  unsettled  whether  the  vascular  effect  of  MPA is  beneficial  or  harmful  







Moreover, oral and transdermal administration of estrogen leads to different estrogenic 
milieus (Kuhl 2005) and thus, the cardiovascular effects of orally and transdermally 
administered HT may differ (Godsland 2001). 
 
The present studies explored the potential impact of hot flushes of different severity on 
various  factors  reflecting  vascular  health  before  and  during  six  months  of  oral  or  











In 2008 in Finland 191 000 women were between 50–54 years of age (Statistics Finland 2009), 
when women typically enter natural menopause (Greendale 1999).  Menopause  is  a  
consequence of the slow deterioration of ovarian function. The primary trigger for ovarian 
senescence is not known, but genetically controlled apoptosis of the ovarian cells is 
involved (Vaskivuo and Tapanainen 2003).  Therefore,  it  is  no  surprise  that  menopausal  age  
shows a significant familial tendency (de Bruin et al. 2001, Murabito et al. 2005). Menopause is 
defined as the onset of the last menstruation, followed by 6–12 months of amenorrhea and 
therefore, this diagnosis can only be made retrospectively. Menopause before the age of 40 
is defined as premature, and it is considered a disease-like condition. Some epidemiological 
factors,  such  as  smoking,  low  body  mass  index  (BMI),  menstrual  irregularities  and  
nulliparity are associated with earlier menopause (Barton  et  al.  2001, Nelson 2008), whereas 
data on the influence of age at menarche and on oral contraceptive use are controversial 
(Harlow and Signorello 2000). Furthermore, socioeconomic factors, such as a low degree of 
education, unemployment or being divorced or widowed are independent risk factors of 
early menopause. Race and ethnicity are also associated with the timing of natural 
menopause (Gold  et  al.  2001), and for instance, Latin women experience menopause 
approximately nine months earlier than non-Latin white women, while Japanese 
race/ethnicity is associated with later menopause (Henderson  et  al.  2008). Furthermore, 
hysterectomy may be associated with 1–2 years earlier onset of menopause (Lobo 2007). It is 
also noteworthy that hypercholesterolemia and hypertension are predisposing factors as 
regards both earlier menopause and CVD (Kok et al. 2006). 
 
During the menopausal transition the level of inhibin B originating from the ovaries 
decreases and the levels of pituitary follicle-stimulating hormone (FSH) and luteinizing 
hormone  (LH)  increase  (Figure  1).  As  the  level  of  FSH  rises,  numerous  small  ovarian  
follicles undergo activation, and this leads to increases in circulating estradiol levels at an 
early stage of menopausal transition. However, this is only a transient phenomenon and is 







With  increasing  age  the  levels  of  FSH  and  LH  continue  to  rise,  but  despite  this,  follicle  
depletion progresses (Burger et al. 2007, Kase 2009). Estradiol produced by the ovaries is the 
main estrogen during the fertile years, whereas after menopause circulating levels of 
estradiol  are  low  (usually  <20  pmol/L),  and  estrone  (usually  <300pmol/L),  produced  by  
aromatization in fatty tissue, is the dominating estrogen after menopause. After menopause 
circulating levels of FSH and LH continue to rise for several years, but in later menopause 
these levels go down. The levels of LH are of importance because they stimulate androgen 
secretion from the ovarian stroma. The ovaries are not the only source of androgens, and 









Figure 1. Schematic presentation of the changes in some reproductive hormones and 













The most typical features of menopause are hot flushes, also referred to as hot flashes or 
vasomotor symptoms, which are present in up to 75–80% of all women in menopausal age 
groups (Dennerstein et al. 2000, Stearns et al. 2002, Deecher and Dorries 2007). The frequency of 
hot  flushes  usually  peaks  within  the  year  of  the  last  menstruation  (Nelson 2008, Santoro 
2008).  In most women hot flushes subside with advancing age, but approximately 20% of 
women continue to have hot flushes several years after menopause, and in many women 
symptoms may persist well into their seventies (Santoro 2008).  
 
Hot  flushes  are  characterized  by  rapid  episodes  of  flushing/reddening  of  the  skin  and  
sensations of heat and sweating. They usually start from the chest and rise up to the neck 
and  face,  and  hot  flushes  may  sometimes  be  followed  by  chills  (Deecher and Dorries 2007, 
Sturdee 2008). Hot flushes are often accompanied by palpitations, anxiousness and broken 
sleep. There is great individual variation in the frequency and severity of flushes, ranging 
from sensations lasting from a few seconds to up to an hour, and reoccurring only seldom 
or almost instantaneously (Nelson 2008). Approximately 20% of women regard hot flushes 
as intolerable (Hickey et  al.  2005, Skurnick et al. 2009), but in almost all women hot flushes 
may to some extent endanger adequate sleep and lead to a number of other symptoms, such 
as nervousness or depressed mood, which are more or less secondary to hot flushes. As a 
net consequence of hot flushes the overall quality of life significantly decreases (Polo-Kantola 
et al. 2001, Utian 2005, Rapkin 2007, Ensrud et al. 2009, Luoto 2009).  
 
The etiology of hot flushes is not known. They seem to be preceded by a rise in core body 
temperature (Freedman 1998) (Figure 2). Several factors may trigger this thermoregulatory 
dysfunction; for instance changes in the circulating concentrations of LH, FSH, estrogens, 
serotonin, norepinephrine, calcitonin gene-related peptide and neuropeptide Y may be 
involved (Barton et al. 2001, Shanafelt et al. 2002, Whiteman  et  al.  2003, Rapkin 2007). 
Fluctuations in estrogen levels that occur during the menopausal transition appear as one 
key  factor  of  the  disturbed  thermoregulation  (Figure  2).  Although  the  impact  of  
hypoestrogenism on hot flushes is indisputable, no clear associations between the levels of 
endogenous sex hormones and the presence or severity of hot flushes have been found 
(Øverlie et al. 2002, Whiteman et al. 2003, Randolph et al. 2005, Götmar et al. 2008, Santoro 2008). 
In contrast, FSH elevations, which reflect the degree of hypoestrogenism, show clear 








The exact details of this thermoregulatory dysfunction in the hypothalamus are not 
understood, but a rise in core body temperature is somehow registered by the narrowed 
thermoregulatory zone in the hypothalamus. This launches heat-dispersal mechanisms, 
partly through changes in the autonomic nervous system, and results in cutaneous 
vasodilatation, flushing and sweating. These compensatory mechanisms may sometimes 
overreact, and chills ensue after hot flushes (Figure 2) (Freedman 2005, Deecher and Dorries 





Figure 2. Possible physiological mechanisms for the initiation of hot flushes (modified from 






Vasomotor symptoms can be reliably evaluated prospectively by using questionnaires in 
which both the frequency and severity of symptoms can be assessed (Table 1). One of the 
most established tests is the Hot Flush Weekly Weighted Score (HFWWS), in which mild 
symptoms are scored with 1, moderate symptoms are score 2, and severe symptoms are 
scored  3  (Sloan  et  al.  2001, Loprinzi and Barton 2009).  With  such a  system it  is  possible  to  
estimate the overall burden of hot flushes, because both their frequency and severity are 
accounted for. Recording hot flushes via such questionnaires mimics a clinical situation 
where a women herself must subjectively approximate the overall impact of hot flushes and 
decide on the possible initiation of HT. For pure research purposes, hot flushes have also 
been objectively quantified by measuring dermal temperature increase and/or changes in 
skin conductance (Sievert 2007). However, such tests are not very sensitive and are prone to 
many errors. Therefore, in clinical research, hot flushes are most commonly assessed by 
means of a subjective scale. This must be completed over a reasonably long period, usually 
for a minimum of 1–2 weeks, because hot flushes show relatively great day-to-day variation 







Table  1.  Hot  flushes  defined  by  the  United  States  Food  and  Drug  Administration  (US 












Hot flushes Definitions 
Absent No hot flushes 
Mild A transient sensation of heat without sweating 
Moderate Sensation of heat accompanied with sweating, but able to continue activities 






There are ethnic differences in hot flushes, and, for example, Asian women show a lower 
incidence of hot flushes (~16%) than Latin, European or African women (~47–57%) (Green 
and  Santoro  2009,  Simpkins  et  al  2009). Cultural differences have been presented as one 
explanation; it is possible that some cultures and languages lack definitions for hot flushes, 
or  that  women are  reluctant  to  express  their  vasomotor  symptoms (Whiteman  et  al.  2003). 
Furthermore, hot flushes also seem more prevalent in regions with large seasonal 
temperature changes (Freeman and Sherif 2007, Sturdee 2008).  
 
Surgical  menopause  is  defined  as  an  oophorectomy in  a  fertile  woman.  This  results  in  an  
abrupt decline in endogenous estrogen levels and often in severe hot flushes soon after 
surgery. Although endogenous estrogen levels show no consistent association with 
vasomotor symptoms (Santoro 2008),  the  presence  of  hot  flushes  has  been  linked  with  
polymorphisms in estrogen-metabolizing cytochrome P450 enzymes (Visvanathan et al. 2005, 
Crandall et al. 2006a, Woods et al. 2006, Schilling et al. 2007), estrogen receptor alpha (ER-α) 
(Malacara et al. 2004)  and  beta  (ER-ß)  (Takeo et al. 2005), and genes that regulate 
angiogenesis (Schneider et al. 2009).  
 
Hot flushes also accompany the use of antiestrogens such as tamoxifen, which is commonly 
used for the adjuvant treatment of breast cancer (Deecher and Dorries 2007, Santoro 2008). 
Smoking and alcohol use may predispose women to hot flushes (Barton et al. 2001, Whiteman 
et al. 2003, Santoro 2008).  It  has  been  thought  that  high  BMI  predisposes  women  to  hot  
flushes as a result of the insulating effect of excess body fat (Freeman and Sherif 2007). On 
the other hand, the conversion of extraglandular androgens to estrogens in fatty tissues has 
been proposed to reduce hot flushes. However, BMI is not a clear-cut determinant of hot 
flushes, since both high and low BMI have been linked with hot flushes. 
 
As evidenced above, menopausal hot flushes, deriving primarily from the central nervous 
system, affect many organs and significantly reduce the quality of life for several years in 
many postmenopausal women. Therefore, reduction of hot flushes has become the primary 















Cardiovascular disease is a major cause of morbidity and mortality in both men and women 
worldwide (The World Health Organization 2007, Shaw et al 2009, van der Schouw 2009). These 
diseases may manifest as angina, coronary heart disease (CHD), myocardial infarction, 
transient cerebral ischemic attacks and stroke (The World Health Organization 2007). Men and 
women differ in their cardiovascular risk profile, and women present with clinically 
significant  disease  approximately  10  years  later  than  men  (Knopp 2002, Pepine  et  al.  2006). 
However,  over  the  past  20  years  the  overall  cardiovascular  risk  profile  in  women  has  
worsened (Towfighi  et  al.  2009),  and  nowadays  the  mortality  of  women as  a  result  of  CVD 
exceeds that of men (Shaw et al. 2009). 
 
It  has been known for many decades that menopause is associated with an increase in the 
incidence of CVD (Kannel et al. 1976, Witteman et al. 1989, Kannel and Wilson 1995, Dubey et al. 
2005, Collins et al. 2007, Shaw et al. 2009). There are many explanations for this phenomenon, 
but menopause-induced hypoestrogenism is the most established one (Mendelsohn and Karas 
1999, Collins 2001, Mendelsohn and Karas 2005). Hypoestrogenism may lead to vascular 
inflammation, endothelial dysfunction and increased arterial stiffness, which all endanger 
vascular health (Kingwell et al. 2001, Staessen et al. 2001, Takahashi  et  al.  2005, Zaydun et al. 
2006). It is also known that blood pressure (BP) increases in many women after menopause 
(Zanchetti  et  al.  2005, Barton and Meyer 2009), but the mechanisms behind this change are 
poorly understood (Casiglia et al. 2008, Cifkova et al. 2008, Coylewright et al. 2008); menopause-
associated  alterations  in  the  function  of  the  autonomic  nervous  system  may  in  part  
contribute to the increase in BP (Vongpatanasin 2009).  In  addition,  patterns  of  the  lipid  
profile deviate in an atherogenic direction in many women during and after menopause 
(Tikkanen 1996b, Rosano et al. 2007). Furthermore, vasoactive prostacyclin, thromboxane and 
endothelins have been linked to the etiology of atherosclerosis alone or through effects on 
lipoproteins (Ylikorkala et al. 1984, Ylikorkala et al. 1987, Mikkola et al. 1995, Ylikorkala et al. 
1995, Mikkola et al. 1996). These biochemical factors and hypoestrogenism-induced changes 
in  them  may  predispose  women  to  the  development  of  CVD.  It  is  further  known  that  
menopause  is  accompanied  by  android  fat  distribution  and  reduced  glucose  tolerance,  in  
other  words,  features  of  metabolic  syndrome;  such  changes  are  seen  in  up  to  40–50% of  
postmenopausal Western women (Kuh et al. 2005, Feng et al. 2008, Janssen et al. 2008, Lobo 
2008). The role of hypoestrogenism in CVD initiation gains further support from the data 
showing that premature menopause and consequent prolonged hypoestrogenism are 







Additional menopausal features  
Further symptoms attributed to the menopause include, for example, sleep disturbances,  
head and joint ache, palpitations, mood changes, oral discomfort and decreased libido (Polo-
Kantola et al. 2001, Utian 2005, Nelson 2008, Ensrud et al. 2009, Meurman et al. 2009, Nappi and 
Lachowsky 2009).  Many  of  these  symptoms,  such  as  broken  sleep,  tiredness  or  depressive  
mood may be secondary to hot flushes. It should also be mentioned that some women may 
be  totally  asymptomatic,  but  nevertheless,  up  95%  of  women  aged  52–56  years  report  at  
least one climacteric symptom (Jokinen et al. 2003). Long-term consequences of menopause 
include atrophy of the vaginal epithelium (Greendale 1999, Santoro and Komi 2009), whereas 
data on the correlation between decreasing estrogen levels and cognitive decline are 
controversial (Barrett-Connor and Laughlin 2009). The association between low estrogen levels 
and bone loss, however, is an established fact (Waugh et al. 2009). It has been calculated that 
a  women  at  50  years  of  age  is  characterized  by  a  30–40%  risk  of  bone  fracture  in  her  
subsequent life; in absolute terms, increased bone loss and fracture risk after menopause are 
very significant determinants of overall quality and even length of life (Huopio  et  al.  2000, 
Sirola  et  al.  2003, Rutanen and Ylikorkala 2004, The Finnish Medical Society and the Academy of 
Finland 2004). 
 
Postmenopausal hormone therapy  
Hormone therapy has been used for approximately 80 years to alleviate hot flushes (Stefanick 
2005). The corner stone in HT is estrogen, which can be administered orally or 
transdermally. Estrogen alone (estrogen-only therapy; ET) can be prescribed to 
hysterectomized women. If a woman has an intact uterus, a progestagen must be added to 
oral or transdermal estrogen treatment (estrogen-progestagen therapy; EPT) to protect 
against endometrial hyperplasia (Farquhar et al. 2009). In Finland in 2008 various forms of 
HT  were  used  by  a  total  of  352  600  postmenopausal  women  (Paakkari et al. 2008). 
Contraindications for HT include a history of breast cancer or other hormone-dependent 
cancer, undiagnosed gynecological bleeding, thromboembolic disease, myocardial infarction, 
stroke, and uncontrolled hypertension (The Finnish Medical Society and the Academy of Finland 
2004). Most liver diseases are cured successfully, and therefore, a sole history of liver disease 
is  no  contraindication  for  the  use  of  HT.  Thus,  women  with  a  history  of  intrahepatic  
cholestasis of pregnancy, for example, tolerate well the use of both oral and transdermal HT 







Natural human estrogens are (17ß-)estradiol, estrone and estriol; estradiol is the most potent 
of these. It binds to estrogen receptors α and ß, but it may also act directly via non-genomic 
mechanisms through cell membrane receptors (Kuhl 2005). In addition to the reproductive 
organs, estrogen receptors can be found in several tissues, e.g. in heart, blood vessels, bone, 
cartilage, skin and the central nervous system. Estrogens are carried in the blood stream 
bound to either sex hormone-binding globulin (SHBG) or albumin, and only 2% of 
circulating estrogens appear free. As a result of mutual conversion between estradiol and 
estrone, the concentrations of these estrogens in the blood are in equilibrium, and both are 
converted in the liver and gastrointestinal system to estriol. Various estrogens differ in their 
binding properties to estrogen receptors, and estrone has only about 4% of the estrogenic 
activity of estradiol (Kuhl 2005).  
 
Estradiol is the drug of choice for menopausal complaints in Europe, whereas in the United 
States CEE is most commonly used. Conjugated equine estrogens, derived from the urine 
of  pregnant  mares,  are  a  mixture  of  several  estrogens,  such  as  17α-  and  17ß-estradiol,  
estrone, equilin and equilenin. Therefore, the composition and even the biological effects of 
CEE may vary (Kuhl 2005).  
 
Estetrol is a new steroid currently being investigated for the management of vasomotor 
symptoms. It was originally isolated from the fetal liver, and in rat models it shows both 
estrogen agonist and antagonist properties (Coelingh Bennink et al 2008, Visser and Coelingh 
Bennink 2009).  So far there are no human data on the use of estetrol for the treatment of 












The  use  of  unopposed  estrogen  in  women  with  an  intact  uterus  is  associated  with  an  
increased risk of endometrial cancer (Stefanick 2005, Furness et al. 2009). Therefore, either a 
sequential progestagen at 10- to 14-day courses each month, or at three-month intervals 
(sequential EPT), or daily (continuous EPT) should be used in combination with estrogen 
(Hickey  et  al.  2005). Progestagens can be administered orally, transdermally, or through an 
intrauterine device (Kuhl 2005). A levonorgestrel-containing intrauterine device (Nilsson et al 
1981, Luukkainen et al. 1986) has proved to be an excellent treatment for menorrhagia 
(Lähteenmäki et al. 1998, Hurskainen et al. 2001), and it can also be used in postmenopausal 
women in combination with ET to ensure endometrial protection (Peled et al 2007, Sitruk-
Ware 2007a).  Progestagens  differ  in  their  affinity  for  steroid  receptors  and their  biological  




Table 2. Biological activity of various progestagens; (++) strong, (+) moderate, (±) weak, (-) 






















       
Progesterone - + - ± + + 
Dydrogesterone - + - - - - 
       
Progesterone-derivative       
Medroxyprogesterone acetate - + ± - ± - 
Megestrol acetate - + ± + + - 
       
Testosterone-derivatives       
Norethisterone - + + - - - 
Levonorgestrel - + + - ± - 
Dienogest ± ± - + - - 
       
Spironolactone-derivative       






Route of administration 
Orally administered estrogens are subject to first-pass metabolism in the liver, unlike 
transdermally administered estradiol. Commonly, estradiol is given in valerate form in oral 
use and as hemihydrate in transdermal use; these agents may slightly affect the estrogenic 
bioprofiles (Kuhl 2005).  Estradiol is given transdermally as a patch or as a gel;  the latter is 
also called percutaneous form of administration. Oral and transdermal administration 
results in different estrogenic milieus; oral estradiol administration causes significantly 
higher circulating levels of estrone than does transdermal use of estradiol. The biological 
responses to oral and transdermal estradiol also differ, especially as regards liver-mediated 
responses (Godsland 2001, Strandberg et al. 2003, Modena et  al.  2005) (Table 3). For instance, 
oral estrogen causes marked beneficial changes in lipids and lipoproteins, whereas lesser 
changes are seen in connection with transdermal estradiol treatment (with the exception of 
triglycerides) (Tikkanen 1996b). Markers of inflammation, such as C-reactive protein and 
adhesion molecules, and metalloproteinases, which affect atherosclerotic plaque stability, 
may be stimulated by oral estradiol, but not transdermal estradiol (Table 3) (Kuhl 2005, 
Mueck and Seeger 2006, Ridker et al. 2008). Use of oral estradiol may also increase the 
production of renin substrate from the liver leading to a consequent release of angiotensin-
II with potential elevation of BP (Mueck and Seeger 2004) (Table 3). Furthermore, individual 
responses  to  oral  and  transdermal  estradiol  vary,  both  in  terms  of  relief  of  vasomotor  
symptoms and increases in the circulating levels of estradiol (Tuimala and Vihtamäki 1996, 
Vihtamäki and Tuimala 1998, Vihtamäki et al. 2004). Thus, a clinician considering the most 
suitable form of HT for a given postmenopausal woman must be aware of these effects as 
well as the patient’s disease history.  
 
 Oral estradiol Transdermal estradiol 
Low-density lipoprotein cholesterol ↓↓ ↓ 
Very low-density lipoprotein cholesterol ↑ ↑ 
Apolipoprotein B ↓↓ ↓ 
Lipoprotein (a) ↓↓ ↓ 
High-density lipoprotein cholesterol ↑↑ ↑ 
Apolipoprotein A ↑↑ ↑ 
Triglycerides ↑↑ ↔ 
Sex hormone-binding globulin ↑↑ ↔ 
C-reactive protein  ↑ ↔ 
Adhesion molecules ↓ ↔ 
Metalloproteinase activity ↑ ↔ 
Renin substrate ↑↑ ↔ 
 
Table 3. Differential effects of oral and transdermal estrogen on various biochemical 
markers; (↓) decrease, (↓↓) substantial decrease, (↑) increase, (↑↑) substantial increase, (↔) 






Effects of hormone therapy  
 
Hot flushes 
Estradiol treatment, with or without a progestagen, is the most effective way to alleviate hot 
flushes. Oral and transdermal HT result in an approximate 75–95% reduction in hot flushes 
in a dose-dependent manner within 2–6 weeks, as demonstrated in several placebo-
controlled studies,  and the addition of daily or sequential  progestagen does not affect this 
efficacy (Maclennan et al. 2004, Nelson 2004, Grady 2006). Recently, the focus has been on 
low-dose regimens; oral doses as low as 0.1–0.5 mg, or transdermal estradiol doses of 0.014 
mg,  can  reduce  hot  flushes  (Panay et al. 2007, van  de  Weijer  et  al.  2007, Langer 2009, Panay 
2009). Progestagens, such as MPA, norethisterone and megestrol, when given without 
estrogen,  may  slightly  alleviate  hot  flushes,  but  alone  they  are  usually  not  used  for  the  
treatment of vasomotor symptoms (Hickey et al. 2005).  
 
Hormone therapy at the lowest effective dose for healthy, recently postmenopausal women 
with disturbing moderate to severe hot flushes is an established treatment recommended by 
a number of expert organizations (Rutanen and Ylikorkala, 2004, The Finnish Medical Society and 
the Academy of Finland 2004, Utian et al. 2008, International Menopause Society Consensus Statement 
2009,). Cessation of HT may lead to reoccurrence of vasomotor symptoms in up to 50% of 
women,  especially  if  hot  flushes  were  moderate  or  severe  at  baseline,  although  the  
symptoms may be milder (Ockene et al. 2005, Ness et al. 2006, Lindh-Åstrand et al. 2009, Lindh-
Åstrand et al. 2010). It is often recommended that the use of HT is stopped for 1–2 months 
every 2–3 years to evaluate whether hot flushes still occur, and if they do, HT can be 
continued (The Finnish Medical Society and the Academy of Finland 2004). The use of HT can be 
continued as long as it improves the quality of life, and therefore, there is no upper limit for 











Because HT has been used for approximately 80 years, abundant clinical data on its effects 
on CVD have accumulated. These data can be considered as being in two categories; 
observational studies and randomized trials on HT. Approximately 40 observational or 
case-controlled studies show a 30–50% lower risk of CVD in users of HT, and therefore, 
until the late 1990s HT was commonly recommended for the prevention of CVD (Colditz et 
al. 1987, Stampfer and Colditz 1991, Grady et al. 1992, Grodstein and Stampfer 1995, Barrett-Connor 














Cardiac death  
n=258 EPT: RR 0.21 (95% CI 0.08–0.59) 
Death due to stroke  









ET: RR 0.75 (95% CI 0.56–0.99) 
EPT: RR 0.69 (95% CI 0.45–0.90) 
Stroke  
n=289 
ET: RR 0.91 (95% CI 0.71–1.17) 
EPT: RR 0.81 (95% CI 0.61–1.10) 
Varas-
Lorenzo 
et al. (2000) 
n=164 769 
5 years 
Myocardial infarction  
n=1242 
ET: OR 0.52 (95% CI 0.35–0.78) 








Coronary heart disease  
n=1253 
ET: RR 0.55 (95% CI 0.45–0.68) 
EPT: RR 0.64 (95% CI 0.49–0.85) 








Coronary heart disease 
n=158 EPT: HR 0.87 (95% CI 0.72–1.05) 
Stroke n=123 EPT: HR 0.86 (95% CI 0.70–1.07) 
 
 
Table 4. Outcomes of some of the largest observational or case-control studies done after 
1995 in which the effects of long-term hormone therapy have been assessed. Abbreviations: 
CI: 95% confidence interval, ET: estrogen-only therapy, EPT: estrogen-progestagen 






The largest observational study was the Nurses’  Health Study (Grodstein et al. 2000), which 
started in 1976. In this study 70 533 postmenopausal women were followed for 20 years and 
data  were  updated  biannually.  The  data  showed  that  current  users  of  ET  (current  at  the  
time) had a 45% reduction in the risk of CHD, which was similar as regards CEE at 0.3 mg 
(risk ratio [RR] 0.58, 95% confidence interval [CI] 0.37–0.92) and CEE at 0.625 mg (RR 
0.54, 95% CI 0.44–0.67), and EPT (Table 4). However, the risk of stroke was increased by 
45% in current users of EPT, and by 35% (RR 1.35, 95% CI 1.08–1.68) in ET users at a 
dose of 0.625 mg, whereas CEE at 0.3 mg did not confer any increase in the risk of stroke 
(RR 0.54, 95% CI 0.28–1.06) (Grodstein et al. 2000) (Table 4). The WHI trial also included an 
observational study arm consisting of 53 054 women of whom 17 503 (33%) were current 
EPT users (Prentice et al. 2005).  During  an  average  follow-up  of  5.5  years  (maximum  8.4  
years) a non-significant protective effect was associated with current HT use (Table 4).  
 
The  protective  effect  of  HT  against  CVD  seen  in  observational  studies  has  in  part  been  
attributed to the “healthy woman effect”, i.e. women who chose HT were in general 
healthier than women who did not use HT. Therefore, randomized, placebo-controlled 
trials,  such as HERS (Hulley et al. 1998, Grady et  al.  2002)  and the WHI trial  (Rossouw et al. 
2002, Manson  et  al.  2003, Anderson et al. 2004) were undertaken. The benefits seen in 
observational studies were, however, not confirmed in these secondary or primary 
prevention trials, showing rather an increased risk of CVD (Herrington and Klein 2003, 
Ylikorkala 2004) (Table 5, a and b).  
 
In the secondary prevention trial HERS the use of CEE at 0.625 mg and MPA at 2.5 mg for 
~4.1 years in older women with established CHD was not associated with increased risk of 
coronary events (RR 0.99, 95% CI 0.80–1.22) or total mortality (RR 1.08, 95% CI 0.84–
1.38). There was, however, a significant trend over time for more coronary events in HT 
users during the first years of use (relative hazard year I:  1.52; year II:  1.00; year III:  0.87; 
year IV: 0.67, p=0.009 for trend) (Hulley et al. 1998). Follow-up after approximately 6.8 years 
showed that the lower rates of coronary events associated with prolonged HT use did not 














Secondary prevention trials 




mean age: 68 
established CHD 
4.1 to 6.8 years  
CEE 0.625 mg + 
MPA 2.5 mg 




mean age: 66 
established CHD 
3.2 years  
CEE 0.625 mg ± 










mean age: 59 
CIMT ≥1mm 
11 months  
oral estradiol 1 mg 
± gestodene 0.025 
mg 
Ultrasound: 
change in CIMT 









estradiol 2mg ± 
4mg cyclic NETA  
Unstable angina, 
proven MI or 
cardiac death 





mean age: 65 
established CHD 
2.8 years  
CEE 0.625 mg ± 
MPA 2.5 mg, and/ 









n=1 017  
mean age: 62 
previous MI 
2 years oral 
estradiol 2mg  MI or death 






mean age: 64 
established CHD 
3.3 years oral 
estradiol 1mg ± 









mean age: 69 
acute coronary 
event <28 days 
1 year oral estradiol 










Table 5a. Secondary prevention studies on hormone therapy. Abbreviations: CEE: 
conjugated equine estrogens, CHD: coronary heart disease, CVD: cardiovascular disease, 
CIMT: carotid intima-media thickness, MI: myocardial infarction, MPA: medroxy-
progesterone acetate, NETA: norethindrone acetate, ±: with or without, +: with. 
 
PHASE: Papworth HRT Atherosclerosis Study (Clarke  et  al.  2002),  HERS  I:  Heart  and  
Estrogen/progestin Study (Hulley et al. 1998), HERS II: Heart and Estrogen/progestin 
Study  (Grady et al. 2002), ERA: Estrogen Replacement Atherosclerosis Trial (Lakoski et al. 
2005), PHOREA: Postmenopausal Hormone Replacement against Atherosclerosis Trial 
(Angerer et al. 2001), WAVE: Women’s Angiographic Vitamin and Estrogen Trial (Waters et 
al. 2002),  ESPRIT:  Estrogen  in  the  Prevention  of  Reinfarction  Trial  (Cherry et al. 2002), 
WELL-HART: Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis 
Regression Trial (Hodis et al. 2003), WHISP: Women's Hormone Intervention Secondary 






The WHI (CEE 0.625 mg with or without MPA) was designed as a primary prevention trial 
of CHD, breast and colorectal cancer and fractures in healthy, postmenopausal women 
between  the  ages  50–79.  The  trial  was  planned  to  continue  for  8.5  years,  but  it  was  
prematurely stopped at 5.2 years because of an increased risk for invasive breast cancer (7 
extra cases/10 000 person-years), and the risks of CHD (7 extra cases/10 000 person-years) 
and stroke (8 extra cases/ 10 000 person-years) were also elevated (Rossouw  et  al.  2002). 
Interestingly, the use of ET in hysterectomized women was not associated with an increased 
risk of CHD (HR 0.91, 95% nominal CI 0.75–1.12) or breast cancer (HR 0.77, 95% 
nominal CI 0.59–1.01), whereas the risk of stroke was elevated (12 more cases/10 000 




Primary prevention trials 




mean age: 62  
LDL cholesterol 
>3.37mmol/L 
2 years oral E2  











mean age: 63 
5.2 years  
CEE 0.625 mg 
+ MPA 2.5 mg 
CHD events 
Hazard ratio 1.29  
(nominal 95% CI 
1.02–1.63)  
Stroke 
Hazard ratio 1.41  





mean age: 64 
6.7 years  
CEE 0.625 mg 
CHD events 
Hazard ratio 0.91  
(nominal 95% CI 
0.75–1.12) 
Stroke 
Hazard ratio 1.39  




Table 5b. Primary prevention studies on hormone therapy. Abbreviations: CEE: conjugated 
equine estrogens, CHD: coronary heart disease, CI: 95% confidence interval, E2: estradiol, 
ET: estrogen only; CIMT: carotid intima-media thickness, LDL: low-density lipoprotein 
cholesterol, MPA: medroxyprogesterone acetate, ±: with or without, +: with.  
 
EPAT: Estrogen in the Prevention of Atherosclerosis Trial (Hodis et al. 2001). WHI-EP: 
Women’s Health Initiative [Estrogen and Progestin] (Rossouw et al. 2002, Manson et al. 2003). 







The WHI trial has received much criticism. For instance, the mean age of the participants in 
the EPT arm was 63 years,  and 4.4% reported previous CHD, stroke or transient cerebral 
ischemia. In other words, they were hardly eligible subjects for a primary prevention trial. 
Moreover, hypertension (36%), smoking (10.5%), hypercholesterolemia (13%) and diabetes 
(4.4%) were common among the study subjects. In addition, 25% had previously used HT 
(Manson et  al.  2003, Anderson et al. 2004).  Thus, the primary prevention nature of the WHI 
trial may be disputed (Grodstein et al. 2003, Mikkola et al. 2004, Mikkola and Ylikorkala 2005).   
 
Several plausible explanations have been suggested for the divergent findings between 
observational studies and randomized clinical trials regarding the cardiovascular benefit of 
HT.  For  instance,  women  who  adhere  to  the  given  treatment,  whether  it  is  active  or  
placebo, tend to have a more beneficial outcome than those with lower compliance to 
treatment.  Differences  in  treatment  regimens,  ET  versus  EPT  and  the  possible  adverse  
effects of MPA, have also been discussed. Furthermore, the length of follow-up has been 
criticized; in observational studies this has been up to 10–20 years, whereas in randomized 
trials it has been only 5–7 years. On the other hand, observational studies can be criticized 
as regards failure to record carefully early clinical events. Time since menopause and a 
woman’s age at the time of HT initiation have been highlighted as key explanatory factors 
for  the  discrepancy  between  results  from  observational  studies  and  randomized  trials.  
Advanced  age  of  study  subjects  in  randomized  trials  may  well  have  been  associated  with  
subclinical atherosclerosis, which manifested during the first years of HT use, whereas the 
arteries in women in observational studies were considerably healthier and were additionally 
protected against atherosclerotic changes during HT use (Mikkola and Clarkson 2002, Waters 
et al. 2002, Grodstein et al. 2003, Herrington and Klein 2003, Mikkola  et  al.  2004, Mikkola and 
















Other organ systems 
Systemic HT affects the whole body, and therefore, all organs possessing estrogen receptors 
are affected by the treatment. The use of estrogen sustains bone structure and restores bone 
mineral density both of which deteriorate after the onset of menopause; the use of estrogen 
results in a reduction of osteoporotic fractures of up to 40–59% (Wells et al. 2002, Farquhar 
et al. 2009). It is also well established that estrogen use is associated with a reduction in the 
risk of colorectal cancer (Hickey  et  al.  2005, Lethaby  et  al.  2008, Farquhar et al. 2009). Most 
observational  studies  have  shown  a  significant  reduction  (up  to  40%)  in  the  risk  of  
Alzheimer’s disease in the users of HT, but the randomized trials have failed to confirm this 
and  in  contrast  showed  an  increase  of  the  risk  of  (vascular)  dementia  (Barrett-Connor and 
Laughlin 2009).  A  two-  to  three-fold  risk  of  venous  thromboembolic  events  is  associated  
with oral HT use (Rachon and Teede 2008, Canonico and Scarabin 2009, Farquhar et al. 2009), but 
this risk seems to be lower or even nonexistent as regards transdermal treatment (Rachon and 
Teede 2008, van de Weijer 2008, Farquhar et al. 2009).  
 
Breast cancer is probably the most feared side effect of HT. The use of HT for over five 
years is associated with a 1.2- to 2.0-fold risk of breast cancer, being higher as regards EPT 
versus ET (Lyytinen et al. 2006, Lyytinen et al. 2009a), with a higher risk for continuous than 
sequential  EPT (Hickey et  al.  2005, Lyytinen et al. 2009a, Lyytinen et al. 2009b). Similarly, the 
use of estradiol and intrauterine progestagen administration has been linked to an elevated 
risk of breast cancer in a non-randomized follow-up study, but this risk elevation may be in 
part  a  result  of  selection  bias;  women  with  a  higher  risk  of  breast  cancer  may  have  been  
treated with an intrauterine progestagen-releasing device (Lyytinen et al. 2010). However, 
continuous  EPT  is  associated  with  a  76%  decrease  in  the  risk  for  endometrial  cancer  

















Other treatment regimens  
 
Although HT is the most effective treatment for hot flushes (Nelson  et  al.  2006), the 
increased  risk  of  breast  cancer  associated  with  HT use  has  led  to  a  search  for  alternative  
treatments. 
 
Tibolone is a synthetic steroid, metabolized to isomers with estrogenic (3α- and 3ß-hydroxy-
tibolone), progestagenic and androgenic (Δ4-tibolone) effects (Kuhl 2005, Notelovitz 2007). 
Tibolone treatment is as effective as HT in reducing hot flushes, but it  does not stimulate 
endometrial growth or increase mammographic breast density (Kuhl 2005, Notelovitz 2007). 
However, the use of tibolone is accompanied by an increased risk of breast cancer (RR 1.36, 
CI 1.15–1.96, in Finnish women, for example) (Lyytinen et al. 2010). This elevation is of the 
same magnitude as that connected with ET. The androgenic properties of tibolone may 
enhance sexual desire, but it also reduces the level of high-density lipoprotein (HDL) 
cholesterol up to 20–30%, which has caused a concern regarding possible vascular risks 
associated  with  its  use.  At  this  stage  it  can  only  be  stated  that  the  vascular  risk  profile  of  
tibolone is not fully explored (Notelovitz 2007, Garefalakis and Hickey 2008, Jernman 2008).  
 
Selective estrogen receptor modulators (SERMs) have either agonistic or antagonistic 
estrogen effects in different tissues. In general, SERMs act as estrogen agonists on bone and 
the cardiovascular system, whereas they act antiestrogenically in the breast (de Villiers 2009). 
However,  SERMs  do  not  alleviate  hot  flushes,  but  instead  may  even  aggravate  or  cause  
them (Cano et al 2007, Shen and Stearns 2009).  There  are  a  number  of  new  SERMs  under  
development, such as ospemifene and bazedoxifene (Rutanen  et  al.  2003, Ylikorkala et al. 
2003, Komi et al. 2005, Lobo et al. 2009, Pinkerton et al. 2009). These compounds show curious 
organ specificity, and, for example, ospemifene strengthens the vaginal epithelium without 
having any effect on the endometrium or the breast (Rutanen et al. 2003, Komi et  al.  2005). 
Thus, in future these compounds may be used as specific targeted therapies against a given 
menopausal symptom, such as atrophy of vaginal epithelium, but none of them have been 
approved for clinical use. 
 
Nonsteroidal treatments include clonidine, selective serotonin and noradrenalin reuptake 
inhibitors, and gabapentin. They are all clearly less effective than estrogen in the treatment 
of hot flushes and also cause a number of side effects (Suvanto-Luukkonen et al. 2005, Grady 
2006, Nelson  et  al.  2006, Sturdee 2008, Shen  and  Stearns  2009). Phytoestrogens may possess 
both estrogenic and antiestrogenic properties, and in some trials significant relief of 






2008). However, placebo-controlled trials have failed to show the efficacy of phytoestrogens 
in reducing hot flushes (Nikander et al. 2003, Lethaby et al. 2007, Henderson et al. 2008). Herbal 
preparations, such as ginseng, evening primrose, dong quai, black cohosh, and vitamin E, 
have shown no or very modest efficacy against hot flushes (Cheema  et  al.  2007, Shen and 
Stearns 2009).  
 
Acupuncture and yoga have been tested, but they show no consistent effect in alleviating 
vasomotor symptoms (Cho  and  Whang  2009, Lee et al. 2009). Physical exercise may slightly 
ameliorate hot flushes, perhaps by increasing hypothalamic and peripheral ß-endorphin 
levels (Daley  et  al.  2009).  In  addition,  life-style  changes  such  as  smoking  cessation  and  
reducing alcohol consumption, the use of fans, layered clothing and diet changes may 
subjectively somewhat alleviate hot flushes (Barton et al. 2001, Santoro 2008, Shen and Stearns 
2009). Some data imply that certain relaxation techniques and paced respiration could also 
be helpful in the management of hot flushes (Hickey et al. 2005, Santoro 2008, Shen and Stearns 
2009).  
 
In summary, despite extensive research, there exists no truly effective non-steroidal 












Assessment of cardiovascular health 
 
It has been recognized that in women CVD is often not diagnosed on time, and even if it is, 
treatment is neglected (Collins et al. 2007, Mikkola 2009). Therefore, several guidelines for 
earlier diagnosis and for more active management of CVD in women have been constructed 
(D'Agostino et  al.  2001, Conroy et al. 2003, Collins et al. 2007, Mosca et  al.  2007). The essential 
feature in these guidelines is active assessment of CVD risk before the condition becomes 
clinically  manifest.   The  risk  of  CVD  is  modified  by  several  factors,  all  of  which  aid  the  
identification of high-risk individuals; such women are targets of primary prevention of 
CVD (Table 6). Known risk factors alone may not be adequate tools for evaluating low-risk 
populations and more sensitive tools are needed, for instance, measurements of arterial 
stiffness and endothelial function. Recently, a multimarker approach that includes the 
evaluation of traditional risk factors in combination with assessment of vascular properties 
and  biomarkers  of  CVD  has  been  suggested  as  a  useful  method  to  assess  the  overall  
cardiovascular risk profile (Hamilton et al. 2007, Ikonomidis et al. 2008).  
 
 
Factors that confer a high risk of cardiovascular disease in women 
Presence of ≥1 
Subclinical target organ damage: 
Presence of ≥3 
cardiovascular risk factors: 
Increased arterial stiffness, ankle-brachial 
index or carotid intima-media thickness Hypercholesterolemia or hypertriglyceridemia 
Impaired renal function Smoking 
Left ventricular hypertrophy Elevated blood pressure 
 Impaired glucose tolerance 
 Abdominal obesity 
Independent risk factors: Age  >65 years 
Hypertension, renal disease, diabetes, 
metabolic syndrome 
Family history of cardiovascular disease: 
women at age <65 years 
men at age <55 years 
Additional risk factors: 
unhealthy diet, physical inactivity, excessive alcohol consumption, 
low socioeconomic status, stress, depression 
 
 
Table 6. Risk factors of cardiovascular disease in women (modified from Mancia et al. 2007, 
Mosca et al. 2007, Ritz 2007, The World Health Organization 2007, Evangelista and McLaughlin  







The endothelium consists of the inner layer of cells on the blood vessel wall, which secretes 
several substances that regulate vascular tone and growth, and modulate inflammation, 
platelet aggregation and coagulation (Koh 2002, Munzel et al. 2008). Vascular tone may be in 
part controlled by the balance between vasodilatory nitric oxide and the vasoconstrictor 
endothelin-1 secreted by the endothelium (Ylikorkala et al. 1998, Koh 2002, Lane et al. 2006, 
Patel and Arora 2008). Hypertension, hypercholesterolemia and hypoestrogenism impair 
endothelial function thus leading to enhanced inflammatory reactions, oxidation of 
lipoproteins, proliferation of vascular smooth muscle cells, changes in extracellular matrix 
constitution, accumulation of lipid-rich material and prothrombotic changes (Koh 2002); all 
these are early steps in the development of atherosclerosis. Endothelial dysfunction may 
also increase arterial stiffness and BP by inducing vasoconstriction (Lane et al. 2006, Wang et 
al. 2008). Thus, endothelial dysfunction is a predisposing factor as regards CVD and it also 
contributes to the clinical progression of these diseases (Lane et al. 2006, Munzel et al. 2008, 





Figure 3. Schematic presentation of factors that cause endothelial dysfunction, and its 







Endothelial function can be assessed, for example, by evaluating the ability of a given blood 
vessel  to  respond  to  vasodilatory  substances,  such  as  salbutamol  and  acetylcholine,  or  to  
reactive hyperemia, all of which cause release of nitric oxide from the endothelium (Patel and 
Arora 2008). This endothelium-dependent vasodilation can be compared with endothelium-
independent vasodilation, which can be triggered by the administration of nitroglycerin, 
which mimics the action of nitric oxide (Sarabi et al. 2001, Hayward et al. 2002, Wilkinson et al. 
2002a, McEniery et al. 2006). The dilatory capacity of a vessel can be measured, for instance, 
by applanation tonometry (pulse wave analysis; PWA) and ultrasonography (flow-mediated 
dilation; FMD) of a distal artery, and finger-pulse plethysmography (Conroy et al. 2003, Kullo 
and Malik 2007). Intracoronary infusion of vasodilatory substances and subsequent 
quantitative coronary angiography is the gold standard of endothelial testing; this technique, 
however,  is  both  invasive  and expensive  (Patel and Arora 2008).  Both  PWA and FMD are  
noninvasive,  but  with  PWA  technology  the  validity  of  measurements  is  controlled  by  a  
quality index calculated by the software. Additional ways to assess endothelial function 
include measuring biomarkers reflecting vascular injury, such as cytokines, inflammation 
markers, circulating endothelial cells and microparticles, and markers of oxidative stress 
(Lane et al. 2006, Munzel et al. 2008).  
 
In addition to endothelial function, blood flow in the arteries is controlled by the stiffness 
of  the  vessels,  which  contributes  both  to  the  velocity  of  the  pulse  wave  and  that  of  the  
waves reflected back from the periphery towards the heart. The loss of vascular elasticity 
due to aging, arteriosclerosis, hypertension or other vascular debilitating factor enhances 
arterial stiffness. This results in an increase in the speed of the forward pressure wave, and 
amplification of the pulse pressure by the reflected wave (Mitchell  et  al.  2004,  Zoungas  and  
Asmar 2007, Wang et al. 2008). Increased arterial stiffness may be associated with endothelial 
dysfunction, alterations in vascular wall matrix proteins, proliferation of smooth muscle 
cells,  inflammation,  and genetic  determinants  may  also  be  involved  (Laurent and Boutouyrie 
2007, Wang et al. 2008). Arterial stiffness can be assessed, for example, by measuring pulse 
transit time (pulse wave velocity), changes in vessel diameter (distensibility), or amplification 
of the pulse pressure caused by the reflected waveform, for instance PWA. Measurement of 
arterial stiffness, either as a surrogate end-point or therapeutic target, has been used in both 
epidemiological studies and clinical trials (Davies and Struthers 2003, Hamilton et al. 2007, 
Zoungas and Asmar 2007, Safar 2008, Wang et al. 2008),  and  it  is  a  valuable  tool  for  the  
assessment of vascular health in individuals with little or no end-organ disease (Zoungas and 







Elevated  BP  is  one  of  the  most  important  cardiovascular  risk  factors  in  both  men  and  
women (Ritz 2007, Barton and Meyer 2009, Evangelista and McLaughlin 2009). Blood pressure is 
considered normal if it is <120/80 mmHg, and hypertensive if it is ≥140/90 mmHg (Mancia 
et al 2007).   However,  it  is  conspicuous  that  BP  without  a  threshold,  for  instance,  high  
normal  (130-139/85-89  mmHg),  confers  an  increased  risk  of  CVD  (Vasan  et  al.  2001, 
Lewington et al. 2002, Svetkey 2005, Kshirsagar et al. 2006, Conen et al. 2007).  
 
Blood pressure is normally measured manually with a mercury sphygmomanometer. This is 
prone to many errors of which the so-called “white coat hypertension” effect is the most 
common. Therefore, for research purposes BP should be measured by means of ambulatory 
monitoring over 24 hours. Ambulatory BP registration enables the assessment of diurnal 
changes and variability in BP that are undetectable with standard BP registrations (Pickering 
et al. 2006, Mancia et al. 2007). Moreover, ambulatory BP can reveal blunted nocturnal falls in 
BP, which are known cardiovascular risk factors (Verdecchia et al. 2007). In clinical trials 
ambulatory BP is considered the gold standard of assessing BP, since this technique enables 
an accurate estimation of 24-hour BPs, and separate analyses of both day- and night time 




The levels of sex hormones have a profound impact on vascular health, as reviewed earlier. 
This concerns not only estrogens, but also progestagens and androgens, although their 
impact on cardiovascular health is less clear (Schindler et al. 2003, Dubey et al. 2005, Karim et al. 
2008, Ouyang et al. 2009). A large body of data shows that low levels of SHBG may indicate 
an elevated risk of CVD in women (Davison and Davis 2003, Rexrode et al. 2003, Karim et al. 
2008, Sowers et al. 2008).  This  association  may  be  related  to  differences  in  endogenous  
estrogen or androgen levels, or insulin resistance (Davison and Davis 2003, Sutton-Tyrrell et al. 
2005, Crandall et al. 2006b, Joffe et al. 2006, Castelao and Gago-Dominguez 2008), since the 









In addition to impaired glucose tolerance (Evangelista and McLaughlin 2009), proatherogenic 
changes, such as elevations in total cholesterol, low-density lipoprotein cholesterol (LDL) or 
triglycerides,  or  a  reduction  in  HDL can  predict  the  risk  of  CVD in  women (Ridker et al. 
2000, Knopp 2002). Further lipid-based CVD markers include apolipoprotein B (apoB) and 
A-I (apoA-I), and their ratio, as well as lipoprotein a [Lp (a)] (Dahlen 1994, Davison and Davis 
2003, Carmena et al. 2004, Chan and Watts 2006, Walldius and Jungner 2006, Suk Danik et al. 
2008). Apolipoprotein B molecules are present in very low-density lipoprotein cholesterol 
(VLDL),  LDL  and  Lp  (a)  and  thus  the  level  of  apoB  indirectly  reflects  the  total  load  of  
circulating atherogenic lipoproteins. In contrast, apoA-I is present only in HDL particles, 
thus representing cardioprotective lipoproteins (Davison and Davis 2003, Chan and Watts 
2006).  
 
Inflammation is a more recently discovered determinant of atherosclerosis and an elevated 
risk of CVD (Lind 2003). It can be detected, for example, by measuring high-sensitivity C-
reactive protein (hs-CRP), fibrinogen, interleukine-6, monocyte-attracting protein-1 and 
adhesion molecules. Of these, hs-CRP is the most established marker (Ridker et al. 2000, 
Davison and Davis 2003, Lind 2003, Mueck and Seeger 2006, Wang et al. 2006, Musunuru et al. 
2008, Packard and Libby 2008). Plasminogen-activator inhibitor-1 and matrix 
metalloproteinase-1, in turn, affect atherosclerotic plaque stability and may predict occlusive 







AIMS OF THE STUDY 
 
The  present  study  was  designed  to  assess  the  impact  of  hot  flushes  on  vascular  health  
variables in recently postmenopausal women before and during various forms of HT.  
 
The specific aims were to compare: 
 
§ Vascular function (Study I), 24-hour ambulatory BP (Study II) and vascular 
biomarkers  (Study  III)  in  women  with  no,  mild,  moderate  or  severe  hot  
flushes 
 
§ Responses  of  the  above-mentioned variables  (Studies  IV–VI)  to  oral  and  











SUBJECTS AND STUDY DESIGN 
 
This study was approved by Helsinki University Women’s Hospital Ethics Committee (no. 
329/E8/03)  and  registered  with  the  National  Agency  for  Medicine  (EudraCT  2004–
005091–16) and the U.S. National Institutes of Health Clinical Research Registry (no. 
NCT00668603).  The  study  was  conducted  according  to  the  principles  of  Good  Clinical  
Practice and the Declaration of Helsinki, and written informed consent was obtained from 
all participants. 
 
The volunteers were recruited via local newspapers between May 2005 and May 2007. 
Nearly 1500 responding women were first interviewed over the telephone by a trained 
research nurse. Four hundred women who met our inclusion criteria (age between 48–55 
years, last menstrual period within the preceding 6–36 months, no previous HT use) were 
invited to record their vasomotor symptoms for two weeks on a structured questionnaire 
that rated the symptoms according to their number and severity (Panay et al. 2007).  
 
Hot flushes were defined as mild if there was only a slight sensation of heat which did not 
disturb  daily  life.  A  moderate  hot  flush  was  a  defined  as  more  intense  sensation  of  heat  
while awake with some perspiration. A severe hot flush was defined as being more intense 
with profuse sweating that clearly interfered with daily life or with sleep (Panay et al. 2007). 
Hot  flushes  were  then  rated  by  using  the  HFWWS,  which  scores  mild  symptoms  as  1,  
moderate symptoms as 2 and severe symptoms as 3 (Notelovitz et al. 2000, Sloan et al. 2001, 




Table 7. Definitions of hot flushes of different degrees of severity.  
HFWWS=Hot Flush Weekly Weighted Score. 
Hot flushes      Definitions Score HFWWS 
Absent 
 





A slight sensation of heat  




Intense sensation of heat while awake  




Intense sensation of heat with profuse sweating  







To be able to accurately distinguish the possible impact of hot flushes on vascular health we 
chose to exclude women with only “intermediate” hot flushes, i.e.  ≥3 mild hot flushes to 
≤7 moderate to severe hot flushes/day. Intermediate hot flushes, smoking, chronic illness 
(such  as  diabetes  or  hypertension  [BP  >140/90  mmHg])  or  use  of  prescription  drugs  
(including current or previous use of HT) were the main causes for the exclusion of 1100 
subjects.  Further  exclusion  criteria  were  a  level  of  FSH  <30  U/L,  BMI  >30  kg/m2, 
hysterectomy, ovariectomy, and unwillingness or inability to comply with the study plan. 
Thus, 150 women were eligible for this study (Figure 4). 
 
For Studies I, II and III the women were classified (based on the HFWWS) as having mild, 
moderate  or  severe  hot  flushes,  or  as  being  totally  asymptomatic  (Table  7,  Figure  4).  At  
baseline 143 women were available for PWA (Study I). Due to hypertensive readings (BP 
>140/90 mmHg) in the ambulatory BP recordings, three women out of 150 were excluded 
from further analysis of ambulatory BP and thus, this study group consisted of 147 women 
(Study II). One hundred and fifty women were eligible for the analysis of vascular 







Figure 4. Gathering of the population for studies on the impact of hot flushes on various 







For the randomized controlled trials on the impact of hot flushes on the responses of CVD 
risk  factors  to  HT  (Studies  IV,  V  and  VI)  the  women  were  classified  as  having  either  
intolerable (≥7 moderate/severe symptoms per day) or tolerable hot flushes (≤hot 3 mild 
symptoms per day). The women were randomized in blocks of four with regard to hot flush 
status (intolerable or tolerable hot flushes) to receive, in a double blind setting, either 1 mg 
of transdermal estradiol hemihydrate gel, 2 mg of oral estradiol valerate with or without 
daily  MPA  at  5  mg,  or  placebo  for  six  months;  these  regimens  were  provided  by  Orion  
Pharma (Espoo, Finland) (Figure 5). All the women used both tablets (active or placebo) 
and gels (placebo or active) to guarantee the double-blind character of the trial. Compliance 
was assessed by counting the unused packages. As a safety precaution, each woman showing 
endometrial thickness of ≥9 mm at six months received MPA (5 mg/day) for two weeks to 
initiate endometrial shedding; this was started after collection of blood samples and all 
relevant clinical data.  In this setting the impact of hot flushes on the responses of arterial  
stiffness  and  endothelial  function  (Study  IV),  ambulatory  BP  (Study  V)  and  biochemical  
markers for CVD (Study VI) to various forms of HT was studied.  
 
On the whole, a very limited number of participants discontinued the trial.  Depending on 
the  study  a  total  of  6  to  9  women  discontinued  for  the  following  reasons:  withdrawal  of  















All participants underwent a thorough physical examination, and findings in pelvic and 
vaginal ultrasonographic examination, Papanicolau smears and endometrial biopsy samples 
were normal.  
Pulse wave analysis and endothelial testing 
 
For Studies I and VI we used PWA (SphygmoCor® 7.0, AtCor Medical, Sydney, Australia). 
In PWA central  aortic waveforms are derived from a series of peripheral pulse waves that 
are  recorded  at  the  radial  artery  with  a  tonometer.  The  central  aortic  pulse  wave  is  then  
calculated using a generalized transfer function, based on the combination of the forward-
moving pressure wave generated by left ventricular systole, and waves reflected back to the 
aorta  from  points  of  greater  impedance  along  the  arterial  tree,  such  as  bifurcations  and  
arterioles (O'Rourke et al. 2001, Mackenzie et al. 2002, Wilkinson et al. 2002a, O'Rourke and Adji 
2005).  
 
Systemic  arterial  stiffness  was  assessed  with  the  augmentation  index  (AIx),  defined  as  the  
difference between the second and the first systolic peaks expressed as a percentage of pulse 
pressure (O'Rourke et al. 2001, Mackenzie et al. 2002, Wilkinson et al. 2002a, O'Rourke and Adji 
2005).  Aortic stiffness was measured from the inflection point after the first systolic peak, 
which marks the time to the return of the reflected wave, dependent on pulse wave velocity, 
and it  can therefore be used as a marker of aortic stiffness (Murgo et al. 1980, London et al. 
1992, Marchais et al. 1993, Wilkinson et al. 2001). Furthermore, left ventricular properties were 
estimated  from the  aortic  pulse  wave,  by  measuring  the  amplitude  and timing  of  the  first  
systolic peak, which are dependent on stroke volume and the rapid phase of ventricular 
ejection, respectively (Wilkinson et al. 2002b) (Figure 6, Table 8).  
 
In the case of increased arterial stiffness, a rise in AIx and a decrease in time to the reflected 
waveform are seen, indicating increased augmentation and a faster return of the reflected 
wave, respectively (Zoungas and Asmar 2007).  Since  AIx  is  influenced  by  heart  rate,  it  was  
normalized to a heart rate of 75beats/min for comparisons (Wilkinson et al. 2000, Wilkinson 
et al. 2002b). For the final analyses the lowest AIx value of three consecutive measurements 








Figure 6. Schematic presentation of the pulse wave before and after nitroglycerin challenge 










Endothelial function was assessed by complementing PWA with nitroglycerin (causes 
endothelium-independent vasodilation) and salbutamol (causes endothelium-dependent 
dilation) challenges, and calculating the endothelial function index (EFI) (Figure 6, Table 8). 
The AIx measurements were carried out before and 3, 5,  10, 15 and 20 minutes after the 
administration of 0.5 mg of sublingual glyceryl trinitrate (Nitro®, Orion Pharma, Espoo, 
Finland).  After  a  60-minute  washout  period  and  a  second  baseline  assessment,  the  
measurements were repeated 5, 10, 15 and 20 minutes after inhalation of 0.4 mg salbutamol 
(Ventoline® Evohaler, GlaxoSmithKline, Ware, UK) (Sarabi et al. 2001, Hayward et al. 2002, 
Wilkinson et al. 2002a, McEniery et al. 2006, Rönnback et al. 2007, Törmälä et al. 2008).  
Ambulatory blood pressure 
The participants wore calibrated oscillometric ambulatory BP monitors (SpaceLabs 90217, 
SpaceLabs Healthcare, Washington, U.S.A.) on their non-dominant arm for 24 hours 
(Studies  II  and V).  The  monitor  was  programmed to  take  readings  at  20-minute  intervals  
during  periods  of  wakefulness  and  at  30-minute  intervals  during  sleep  according  to  each  
participant’s estimated bedtime. The women were instructed to maintain their normal daily 
activities during the ambulatory BP recordings, and to record their activities and vasomotor 
symptoms in a diary. States of wakefulness and sleep state were defined according to diary 
entries.  
 
All successful measurements of systolic and diastolic BP, together with simultaneous heart 
rate and the exact time of the measurement were transferred from the ambulatory BP 
system to a spreadsheet for further analysis of 24-h BP and heart rate, and separate analyses 
for daytime and night-time. Pulse pressure was defined as systolic minus diastolic BP, and 
absolute dipping was defined as the difference between average systolic BPs awake and 
asleep. Relative dipping was calculated as the percentage of absolute dipping of systolic BP 
when awake, and relative dipping of at least 10% was considered a normal dipping pattern 
(Pickering et al. 2006). The acute effects of hot flushes on BP were analyzed from night-time 
measurements in women with severe hot flushes. Diaries were used to identify the exact 
time of the hot flush. A recording occurring within 15 minutes after a hot flush was defined 
as  representing  the  BP  and  heart  rate  during  and  after  a  hot  flush,  and  the  data  were  
compared with the average BP and heart rate at night-time. We were able to identify 44 
such hot flush episodes among 26 women, and in case of multiple hot flush experiences the 






Assays for biochemical markers for cardiovascular disease 
 
Fasting blood samples were collected and serum was separated with centrifugation. Samples 
at 6 months were scheduled to be collected approximately two hours after the intake of the 
study medication. Serum samples, kept frozen in -80ºC, were assayed for total cholesterol, 
HDL, LDL, VLDL and triglycerides using standard methods (Havel et al. 1955). 
Commercially  available  kits  were  employed  for  apoB,  apoA-I  and  Lp  (a),  SHBG  and  hs-
CRP and estradiol. The level of estrone was assayed by liquid chromatography-tandem mass 
spectrometry based on the method of Nelson et al  (2004) with some modifications (Study 
III). The free estradiol index (FEI) was calculated as the ratio: estradiol (nmol/L) 
x100/SHBG (nmol/L) (Table 9). Thyroid-stimulating hormone was tested using 
chemiluminescent microparticle immunoassay (Abbott Diagnostics, Abbott Park, IL) and 
FSH was analyzed by time resolved immunofluorometric assay method (AutoDelfia™, 




Table 9. Characteristics of the assays used for the measurement of biochemical markers of 
cardiovascular disease. *=for low and high concentrations, respectively.   
Analyte Source Principle of assay 
Coefficient of variation Detection 
limit Intra-assay Interassay 
Total cholesterol Thermo Electron Co  KonelabTM Vantaa, Finland 
Enzymatic  




density, and very  
low-density lipo-
protein cholesterols 
 Ultracentrifugation 0.42–1.3%* 1.5–2.2%* 0.084 mmol/L 
Triglycerides Thermo Electron Co  KonelabTM Vantaa, Finland 
Enzymatic  
colorimetry 1.0–1.9%* 2.0–2.5%* 
0.02 
mmol/L 
Lipoprotein (a) Thermo Electron Co KonelabTM Vantaa, Finland Immunoprecipitation 1.3–2.6%* 2.7–3.5%* 30 mg/L 
Apolipoprotein B  Thermo Electron Co  KonelabTM Vantaa, Finland Immunoprecipitation 1.6–1.7%* 2.8– 3.4%* 50 mg/L 
Apolipoprotein  
A-I 
Thermo Electron Co  









Orion Diagnostica Oy 
 Espoo, Finland Immunoturbidimetry 0.3–6.6%* 2.1–11.9%* 
0.25 
mg/L 
Estrone CDN Isotopes Inc. Pointe-Claire, Canada 
Liquid chromatography-

















Power  analysis  was  made  with  the  anticipated  mean  change  in  PWA  in  response  to  HT  
estimated to be 6.6% with a standard deviation (SD) of 1. The comparisons were calculated 
to achieve 80% power to detect a 15% difference in the responses to HT between women 
with  intolerable  and  tolerable  hot  flushes  at  a  conventional  alpha-level  of  0.05.  The  
responses in biochemical markers and ambulatory BP were secondary endpoints of this trial.  
 
Normality was assessed with the Shapiro–Wilk test. Logarithmic transformations and 
inverse transformation were made to achieve normal distribution, or the data was converted 







































groups analysis of 
covariance 
with Tukey HSD 
and Games–
Howell post hoc 
comparisons 
Linear regression 
analysis    
Non-parametric tests for variables with non-normal distribution 
Kruskall–Wallis 






















When appropriate, analyses were conducted adjusting for the time since menopause and the 
levels of estrone, estradiol and the FEI. Owing to multicollinearity between variables, a 
univariable instead of a multivariable approach was used (Studies IV and V) and partial eta² 
(η²)  was  calculated  to  describe  the  proportion  of  variance  in  the  variables  explained  by  
treatment. Tukey HSD and Games–Howell post hoc comparisons were used for variables 
with equal and unequal variances, respectively. Due to significant interaction between hot 
flush status and the effect of treatment in Studies IV and V separate analyses were carried 
out for women with intolerable and tolerable hot flushes (Study IV), and the different 
treatment groups (Study V). A p-value <0.05 was considered statistically significant. All data 
are presented as mean±SD or mean±standard error of the mean (SEM). All analyses were 









Detailed results are given in the original publications and only the main results are presented 
here. 
 
Impact of hot flushes on vascular health 
 
Women with no, mild, moderate, or severe hot flushes were comparable in age, weight, 
height, BMI, and the level of thyroid-stimulating hormone. Importantly, there were no 
significant differences in the serum levels of estrone, estradiol, or the FEI. A significant 
trend was observed for the time since the last menstruation to be shorter with increasing 
severity of hot flushes, being approximately 6 months between asymptomatic women and 
those with severe hot flushes (Study I p=0.006;  Study II p=0.004; Study III p=0.006 [p-for-
trend]). 
 
Vascular function (Study I)  
In PWA after the challenge with nitroglycerin, time to peak ejection was 12.3% (p=0.025) 
longer  and time to  reflected  waveform was  9.2% (p=0.014)  longer  in  women with  severe  
hot flushes as compared with asymptomatic women. A significant trend across the groups 
was  also  detected;  both  time  to  peak  ejection  and  time  to  reflected  waveform  after  
nitroglycerin were longer with increasing severity of hot flushes (p=0.001 and p=0.002, 
respectively). No effect of salbutamol was seen in any of the study groups. Hot flush status 
did  not  influence  arterial  (AIx)  or  aortic  stiffness  (time  to  reflected  waveform),  or  













Table 11. Variables in pulse wave analysis before and after challenges with nitroglycerin and 
salbutamol. ns=non-significant, †=p for the difference between asymptomatic women and 










Hot flushes  None Mild Moderate Severe p-value 
Augmentation index 23.7±1.7 22.6±1.4 22.0±1.3 22.1±1.1 ns 
Endothelial function index 21.3±11.2 37.7±16.1 24.7±6.2 26.7±5.2 ns 
Time to peak ejection  
at baseline 
106.5±2.1 110.1±2.2 113.0±2.2 107.7±2.0 ns 
Time to peak ejection  
after nitroglycerin 
115.5±3.5 120.2±3.7 127.6±4.6 131.5±3.4 0.025 †; 
0.001 ‡ 
Time to peak ejection  
after salbutamol 
109.1±3.0 106.9±1.7 112.8±2.7 110.7±1.8 ns 
Time to reflected waveform 
at baseline 
138.9±2.2 143.2±2.2 145.3±1.7 141.4±2.1 ns 
Time to reflected waveform 
after nitroglycerin 
149.8±2.2 157.6±3.2 159.4±3.3 164.0±2.6 0.014 †; 
0.002 ‡ 
Time to reflected waveform 
after salbutamol 






Ambulatory blood pressure (Study II)  
 
Women with different severity of hot flushes were fully comparable in their 24-hour BP and 
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Figure 7. Mean contours of blood pressure and heart rate during 24 hours in women with 
no,  mild  moderate  or  severe  hot  flushes.  Reprinted  and slightly  modified  with  permission  

















However, severe night-time hot flushes were accompanied by transient increases in systolic 
(4.1±10.5 mmHg, p=0.061) and diastolic BP (3.1±6.8 mmHg, p=0.032), and heart rate 








Figure 8. Impact of severe night-time hot flushes on ambulatory blood pressure and heart 
rate during 44 hot flush episodes in 26 women. Data are presented as mean±SD. A p-value 
<0.05 was considered statistically significant. Reprinted and slightly modified with 













Biochemical markers for cardiovascular disease (Study III) 
Hot flush status was not a determinant for the levels of lipids, lipoproteins, apolipoproteins 
or  the  ApoB/ApoA-1  ratio.  Moreover,  the  levels  of  SHBG  and  hs-CRP  were  similar  in  
women with no, mild, moderate or severe hot flushes. Estrogenic variables were also 
comparable between the study groups (Figure 9). 
 















































Figure  9.  Levels  of  estrogens  and  biochemical  markers  of  cardiovascular  disease  in  








Randomized trial on hormone therapy 
 
All active treatments were equally effective in reducing vasomotor symptoms in women 
with  intolerable  hot  flushes,  whereas  no  effect  was  seen  in  women  with  tolerable  hot  
flushes. All treatments irrespective of hot flush status caused significant rises in estrone and 
estradiol  levels  compared  with  placebo (p<0.001 for all). Transdermal estradiol caused an 
approximate 3-fold rise in estrone levels, which was smaller than the rises resulting from 
oral estradiol treatment with or without MPA (14-fold and 20-fold, respectively, p<0.001 for 
both). The rises in estradiol levels (approximately 3-4-fold) were comparable between all 
three active treatments.  
 
Responses of 
Vascular function (Study IV) 
In women with tolerable hot flushes, oral estradiol caused significant (p<0.05) reductions in 
both  time  to  peak  ejection  (~13%)  and  time  to  reflected  waveform  (~8%)  after  
nitroglycerin as compared with the increases caused by transdermal estradiol (~11 and 
~6%, respectively), oral estradiol complemented with MPA (~11% and ~7%, respectively), 
or placebo treatment (~8% and ~6%, respectively) (Figure 10). These changes were 
independent of time since menopause and changes in the levels of estrogens. In women 
with intolerable hot flushes both time to peak ejection and time to reflected waveform after 
nitroglycerin remained unaffected in all treatment groups. Overall, arterial stiffness (AIx) 
and endothelial function (EFI) were unaffected by the different treatment regimens or hot 
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Figure 10. Vascular responses to different hormone therapy regimens and placebo. Time to 
peak ejection after nitroglycerin in women with intolerable (Panel A) and tolerable hot 
flushes (Panel B). Time to reflected waveform after nitroglycerin in women with intolerable 
(Panel C) and tolerable hot flushes (Panel D). Data presented as percentage of baseline with 
line  at  mean.  A two-tailed  p-value <0.05 was considered statistically significant. Reprinted 














Ambulatory blood pressure (Study V) 
Hot flush status was a significant determinant of the responses to HT of both 24-hour and 
daytime systolic and diastolic BPs. In women with tolerable hot flushes taking oral estradiol 
24-hour systolic and diastolic BPs rose (3.7±1.2 mmHg and 1.8±0.8 mmHg, respectively),  
whereas decreases (-1.2±1.2 mmHg and -2.1±0.8 mmHg, respectively) were detected in 
women with intolerable hot flushes (p=0.010 and p=0.003, respectively (Figure 11). 
Similarly, daytime systolic and diastolic BPs increased (3.0±1.3 mmHg and 1.8±0.9 mmHg, 
respectively) in women with tolerable hot flushes receiving oral estradiol, but the same 
therapy led to falls (-1.9±1.3 mmHg and -2.4±0.9 mmHg, respectively) in women with 
intolerable hot flushes (p=0.017 and p=0.003, respectively) (Figure 11). A tendency towards 
similar responses was observed for night-time systolic and diastolic BPs, but these did not 
reach statistical significance. Transdermal estradiol and oral estradiol complemented with 
MPA caused comparable responses in 24-hour, daytime and night-time BPs. Furthermore, 
in  women  with  tolerable  hot  flushes  the  use  of  transdermal  estradiol  led  to  significant  
decreases in 24-h systolic and diastolic BPs compared with the increases caused by oral 
estradiol (p=0.001 and p=0.041, respectively). Hot flush status was not a determinant of the 
responses in heart rate or nocturnal dipping to the different treatment regimens. The 
baseline  levels  were  significant  determinants  of  the  changes  in  BPs  and heart  rate,  but  no  
dependence on time since menopause or changes in levels of estrone, estradiol, or the FEI 
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Figure 11. Effect of oral estradiol on 24-hour and daytime systolic and diastolic BPs in 
women with tolerable and intolerable hot flushes. Data presented as mean ± SEM adjusted 






Biochemical markers for cardiovascular disease (Study VI) 
Hot  flush  status  did  not  affect  the  responses  of  biochemical  markers  for  CVD to  various  
forms  of  HT.  When  all  active  treatments  (estradiol  administered  either  transdermally,  or  
orally;  alone or together with MPA) were assessed together,  7 out of 10 markers,  i.e.  total  
cholesterol, LDL, VLDL and HDL cholesterols, apoB, SHBG and hs-CRP, showed more 
beneficial changes during estradiol use in women with intolerable versus tolerable hot 
flushes,  whereas  the  changes  in  triglycerides,  Lp  (a)  and  apoA-I  were  more  favorable  in  
women with tolerable hot flushes. Furthermore, in women with intolerable hot flushes 
treated with any form of estradiol, the rises in serum SHBG concentrations (~73%, n=45, 
Spearman’s rho -0.570, p<0.001) were related to falls in HFWWS, but no other statistically 
significant relations emerged (Figure 12).  
 
On  the  whole,  oral  estradiol  caused  significant  increases  in  HDL  (~13.5%),  apoA-1  
(~10.5%),  SHBG  (~116.7%),  and  hs-CRP  (~110.3%)  as  compared  with  placebo.  Adding  
MPA to oral estradiol treatment significantly blunted the rises of both HDL (~6.4%) and 
SHBG levels (~50.3%), and caused a significant reduction (~-7.9%) in total cholesterol 
levels. Compared with placebo transdermal estradiol was effective only in decreasing levels 
of apoB (-7.8%). Analyses were controlled for the influence of time since menopause and 









Figure 12.  
Correlations between the 
decreases in the HFWWS and 
changes in SHBG and LDL 
cholesterol levels in women 
with intolerable hot flushes at 
baseline after receiving six 
months of any hormone 
therapy. A two-tailed p-value 
<0.05 was considered statisti-


















Spearman´s rho 0.306, p=0.061
LDL Cholesterol








Several experimental and human data imply that hypoestrogenism is associated with 
accelerated atherosclerosis (Mikkola and Clarkson 2002).  This,  at  least  in  part,  may  explain  
the increase in the risk of CVD in postmenopausal women (Shaw et al. 2009), and also the 
fact data that postmenopausal HT has been accompanied with a 40–50% reduction in the 
incidence of CVD in observational studies (Stampfer and Colditz 1991, Grady  et  al.  1992, 
Grodstein et al. 2000). These findings, however, were not confirmed in randomized, placebo-
controlled trials, which showed not only a lack of benefits, but rather cardiovascular harm in 
the early phase of HT use (Hulley et al. 1998, Grady et al. 2002, Rossouw et al. 2002, Manson et 
al. 2003, Anderson et al. 2004). Exploring the possible explanations for these divergent data 
was one primary goal of my research, and thus, I explored the role of postmenopausal hot 
flushes in connection with cardiovascular health. 
 
After the initiation of my study, data have accumulated to show that a woman’s age and the 
time since the last menstruation may significantly alter the cardiovascular effects of HT with 
potential harm accumulating in the more elderly women (Grodstein et al. 2006, Hsia et al. 
2006, Ouyang et al. 2006, Lobo 2007, Manson et al. 2007, Rossouw et al. 2007, Hernan et al. 2008, 
Vitale et al. 2008). This may be related to the decrease of estrogen receptors in vascular walls 
with advancing age (Kuhl 2005). Moreover, it is possible that early atherosclerotic changes, 
which unavoidably develop in each individual, enhance the risk of vascular harm associated 
with HT. In other words, the effects of HT may be deleterious in diseased blood vessels 
even though they are beneficial in healthy blood vessels (Mikkola and Clarkson 2002). 
Therefore,  there  may  be  a  window (age  or  time since  menopause)  for  the  opportunity  to  
prevent CVD by HT; early initiation of HT may be protective, whereas late initiation may 
be detrimental (Mikkola  and  Clarkson  2002, Mikkola and Ylikorkala 2005, Mikkola and 
Clarkson 2006). This theory is also supported by later analyses of WHI data (Hsia et al. 2006, 
Manson  et  al.  2007, Rossouw et al. 2007),  although  not  all  experts  seem  to  share  this  view  
(Prentice et al. 2009).  To  conclude,  the  current  understanding  is  that  the  use  of  HT  is  
protective against CVD in healthy women between 50–59 years, but not protective and 











The presence of vasomotor hot flushes has emerged as one possible contributing factor for 
the divergent results (Mikkola and Ylikorkala 2005, van  der  Schouw  and  Grobbee  2005, 
Mendelsohn and Karas 2007, Allison and Manson 2009, Andrikoula et al. 2009, Pinkerton and 
Stovall 2009). In clinical practice, women with troublesome hot flushes seek HT treatment, 
and  thus,  such  women were  included into  HT users  in  observational  studies  (Mikkola and 
Ylikorkala 2005).  In  contrast,  hot  flushes  were  mild  or  absent  in  the  majority  of  women  
taking  part  in  the  WHI trial,  for  example,  in  part  as  a  result  of  the  fact  that  women with  
severe vasomotor symptoms would not comply with possibly being randomized to a 
placebo group (The Women’s Health Initiative Study Group 1998).  
  
Differences in the cardiovascular effects of HT have also in part been attributed to varying 
contents of hormone regimens, i.e.  the relative high dose of CEE 0.625mg and the use of 
continuous MPA, which were the compounds used both in the HERS and the WHI trials 
(Grodstein et al. 2003, van der Schouw and Grobbee 2005, Kuhl and Stevenson 2006). The impact of 
MPA on the vascular effects of HT has been particularly widely debated (Clarkson and Appt 
2003, Koh  and  Sakuma 2004, Kuhl and Stevenson 2006). This progestagen has antiestrogenic, 
androgenic and glucocorticoid properties which may counteract the beneficial effects of 
estrogen (Kuhl 2005, Sitruk-Ware 2007b). Thus, it is possible that the vascular responses to 
estrogen  with  and  without  MPA  differ  (Adams  et  al.  1997, Sitruk-Ware 2000, Kawano et al. 
2001), although this is not supported by the results of all clinical studies (Clarkson and Appt 
2003, Yeboah  et  al.  2007).  It  is  also  known  that  adding  MPA  to  the  regimen  may  prevent  
estrogen-induced rises in biomarkers (Godsland 2001, Shulman 2002). For instance, oral 
estrogen alone or in combination with low-dose MPA (2.5 mg/day) increases the levels of 
C-reactive protein, but not if oral estrogen is accompanied by a higher dose (5.0 mg/day) of 
MPA (Wakatsuki et al. 2002). Furthermore, it is known that the addition of MPA to estradiol 
for  two weeks  does  not  affect  the  responses  of  SHBG or  hs-CRP to  oral  estradiol  alone  
(Ropponen et al. 2005a, Ropponen et al. 2005b). Since the data regarding MPA are diverse, it was 
of  special  interest  to  investigate  the  effects  of  this  progestagen  in  my  study.  As  regards  
estrogen,  CEE  contains  a  variable  mixture  of  at  least  ten  estrogen  sulfates,  only  three  of  
which are produced in humans, and may therefore yield different clinical effects (Kuhl 2005). 
Thus, to be able to adequately determine the specific effects of estrogen, estradiol was 
chosen as the estrogen component for my study.  
 
To assess the impact of hot flushes, the study population was carefully chosen to represent 
healthy, postmenopausal women with no known cardiovascular risk factors. Additional 
strengths of my study include the use of prospective recording and validated scoring of hot 
flushes, which enables accurate assessment of vasomotor symptoms (Sloan  et  al.  2001). 






be the most representative tool to assess the overall cardiovascular health (Ikonomidis et al. 
2008). The following points should be acknowledged. Firstly, PWA provides assessment of 
both structural and functional properties of arteries, especially if combined with endothelial 
testing (Davies and Struthers 2003, Hirata et al. 2006, Kullo and Malik 2007, Wittrock et al. 2008). 
Secondly,  BP  was  measured  over  24  hours  with  ambulatory  BP  registration,  which  is  the  
gold  standard  of  BP  assessment  in  clinical  research  (Pickering et al. 2006). Thirdly, the 
atherosclerotic and inflammatory burdens of the vascular bed were evaluated with 
established biochemical markers for CVD (Ridker  et  al.  2000, Knopp 2002, Carmena et al. 
2004, Chan and Watts 2006).  
 
After the baseline assessments the study subjects were randomized to oral and transdermal 
estradiol  at  equipotent  doses  (Kuhl 2005, Panay 2009), which enabled comparison of the 
impact of different routes of estradiol administration. It was already known before the 
design of the present study that the cardiovascular effects of orally and transdermally 
administered HT may differ (Godsland 2001), and this evidence became stronger during the 
study (Khalil 2005, Modena et al. 2005, Clarkson and Karas 2007, Hemelaar et al. 2008, L'Hermite 
et al. 2008). 
 
As limitations of the study I acknowledge that the study population consisted of lean, white 
women and thus my results are not be generalizable to obese women or women belonging 
to other ethnic groups. Moreover,  I  studied  only  normotensive  women,  and the  effect  of  
HT in hypertensive women may be different. This reservation is significant; many 
postmenopausal women show slightly elevated BP, perhaps as a consequence of hot flushes 
(Vongpatanasin 2009) and, in theory, the effect of HT might be most conspicuous in women 
with  hot  flushes  and  mildly  elevated  BP.  Furthermore,  my  study  subjects  had  entered  
menopause within the preceding 0.5 to 3 years, so my data may not hold for older women 
with longer postmenopausal age accumulation. In addition, HT was given only for six 
months and a longer treatment period might have yielded additional differences. However, 
2-  to  6-month  HT treatments  have  commonly  been  used  in  HT studies  (Mueck and Seeger 
2004, Teede 2007). In addition, estradiol was given at conventional doses, and modern low 
doses may show different effects (Langer 2009).  Moreover,  my data may not be applicable 
for other estrogen/progestagen combinations. Finally, I studied a limited number of women 
and therefore, it possible that some changes remained undetected due to the small sample 
sizes. However, the power of the study was calculated to detect the impact of hot flushes on 











Menopause may increase arterial stiffness, perhaps as a consequence of hypoestrogenism 
(Takahashi  et  al.  2005, Zaydun  et  al.  2006). Older data have shown increased venous blood 
flow in the upper extremities of flushing women (Ginsburg et al. 1981, Ginsburg et al. 1989). 
My data demonstrate that increasing severity of hot flushes is accompanied by an arterial 
vasodilatory feature, as evidenced by prolongations of the times to peak ejection and 
reflected waveform after the nitroglycerin challenge. This may indicate a favorable vascular 
feature in women with hot flushes of different severities. The presence of hot flushes was 
not associated with any changes in arterial stiffness or endothelial function (Study I).  
 
During the course of my study some data have emerged that suggest lower FMD in women 
with hot flushes (Thurston et al. 2008a). There are marked differences between my study and 
that of Thurston and coworkers. First, the women studied by Thurston and colleagues were 
obese  (mean  BMI  29  kg/m²),  whereas  participants  in  my  study  were  lean  (mean  BMI  23  
kg/m²)  (Study  I).  Second,  approximately  one  third  of  the  participants  in  Thurston’s  study  
were  African-American  women  who  are  known  to  have  in  general  a  less  favorable  
cardiovascular risk profile (Winkleby et al. 1998), whereas I studied Caucasian women.  Third, 
the population in the study by Thurston et al. included also women using HT, and thus they 
cannot  be  compared  with  the  HT-naïve  women  in  my  study.  Finally,  and  perhaps  most  
importantly, hot flushes were retrospectively recalled and the estradiol levels were almost 
twice  as  high  in  flushing  women  as  in  women  without  hot  flushes  (Thurston et al. 2008a), 
whereas hot flushes in my study were prospectively recorded and the study groups did not 
differ in estradiol levels (Studies I, II and III).   
 
Besides studying the impact of hot flushes on vascular variables in a cross-sectional setting, 
the present study evaluated the impact of hot flushes on outcomes of HT in a prospective, 
randomized trial. Previous data on the impact of HT on vascular function are inconclusive 
due to the diversity in study methodologies (Ganz 2002, Koh 2002, Teede 2007, Bechlioulis et al. 
2009),  but  in  some studies  HT has  been  shown to  reduce  arterial  and  aortic  stiffness  and 
improve endothelial function (Hayward et al. 1997, Miura et al. 2003, Sztejnsznajd et al. 2006, 
Vitale et al. 2008).  In  my  study  the  use  of  oral  estradiol  was  associated  with  significant  
reductions  in  times  to  both  peak  ejection  and  reflected  waveform  after  nitroglycerin,  but  
only in women with tolerable hot flushes (Study IV). This can be seen as a vasoconstrictive 
response to oral estradiol in these women. Interestingly, in women with intolerable hot 
flushes, the responses to transdermal estradiol or oral estradiol with or without concomitant 
MPA were neutral in terms of vasoconstriction or vasodilation. Arterial stiffness and 






Thus, taken as a whole, the route of estrogen appears to be a critical factor; the transdermal 




Ambulatory blood pressure 
 
Elevations in sympathetic nervous activity due to hypoestrogenism are found in women 
with vasomotor symptoms (Freedman 2005, Deecher and Dorries 2007, Sturdee 2008), and this 
could  result  in  elevated  BP (Coylewright et al. 2008, Vongpatanasin 2009).  Prior  to  my study  
some data implied that hot flushes were associated with an increase in either office (Beljic et 
al. 1999)  or  ambulatory  BP (Brown et al. 2001, James  et  al.  2004).  During  the  course  of  my 
study additional data from cross-sectional studies have shown an association between hot 
flushes and increases in office (Gast et al. 2008, Thurston et al. 2008a, Gallicchio et al. 2009) or 
ambulatory BP (Gerber et al. 2007). However, none of these studies utilized the 
recommended procedure of prospective hot flush recording, but rather a retrospective 
recall, which certainly is inaccurate (Pinkerton and Stovall 2009). Furthermore, these studies 
included  smokers  (Brown et al. 2001, James  et  al.  2004, Gerber et al. 2007, Gast  et  al.  2008, 
Thurston et al. 2008a, Gallicchio et al. 2009) and hypertensive women (Gerber et al. 2007, Gast et 
al. 2008, Gallicchio et al. 2009) and thus these data are not generalizable to a healthy and HT-
naïve  population  as  I  studied;  my  study  population  represents  the  majority  of  women  
considering  the  use  of  HT  in  routine  clinical  practice.  Hot  flushes  have  been  shown  to  
associate with simultaneous increases (Freedman and Dinsay 2000, Low et al. 2008) or 
decreases  in  BP  (Nelesen et al. 2004). My  data  show  that  severe  hot  flushes  are  associated  
with increases in night-time diastolic BP and heart rate. However, these increases were so 
short that on the whole, the overall effect of hot flushes on diurnal BP was negligible (Study 
II).  However,  heart  rate  variability  may  be  a  more  sensitive  marker  of  cardiovascular  
function than sole heart rate or BP, and this variability shows an interesting association with 
severe hot flushes (Hoikkala et al. 2010).  
 
Hormone therapy modifies a number of vasoregulators,  and therefore, HT may affect BP 
(Luotola 1983, Khalil 2005, Koledova and Khalil 2007). The progestagen component in HT may 
also modify BP. For instance, drospirenone, a recently introduced progestagen with 
antimineralocorticoid activity, present both in oral contraceptive pills and menopausal EPT 
regimens (Anttila  et  al.  2009),  may  lower  BP  (Nath and Sitruk-Ware 2009, Preston 2009). 
Decreases in BP have been associated with transdermal estradiol use (Cacciatore et al. 2001, 
Mueck and Seeger 2004, L'Hermite et al. 2008). On the other hand, oral estradiol may increase 






release of angiotensin-II, one of the most potent hypertensive agents (Miller and Duckles 
2008). My data show that the presence of hot flushes affects BP responses according to the 
type of HT (Study V). In women with tolerable hot flushes oral estradiol was accompanied 
by increases in both 24-h and daytime BPs, whereas no such effect was seen in women with 
intolerable hot flushes. This is clinically significant; the former group is usually not a 
candidate for hormone use, whereas the latter women typically are. Deterioration in the 
diurnal variation of BP may occur in menopause and HT may improve this by increasing 
nocturnal BP dipping (Butkevich  et  al.  2000, Wong  et  al.  2005). My data, however, did not 
show such an effect of HT, perhaps because all  participants already had a normal dipping 
pattern at baseline. The situation might have been different if older women or women with 
mildly elevated BP were to have been included. 
 
The message for the clinician reads; if a symptomless woman needs estrogen for a reason 
other than for the control of hot flushes, favor transdermal administration, because this may 




Vascular biochemical markers  
 
When this study was planned, only a reduced antioxidant status was known to be related to 
hot flushes (Leal et al. 2000).  During my study, data were published linking hot flushes to 
risk  factors  of  CVD,  such  as  increased  abdominal  adiposity  (Thurston et al. 2008b) and 
elevated cholesterol levels (Gast et al. 2008, Thurston et al. 2008a). However, the majority of 
the studies were cross-sectional studies that included pre-, peri- and postmenopausal 
women, and women on HT or tobacco users, and women with hypertension and therefore, 
the results may not truly reflect the causality between hot flushes and various markers for 
CVD. My data, concerning in healthy, recently postmenopausal women, show no 
association between baseline hot flush status and biochemical markers for CVD (Study III). 
 
There are no previous data on the impact of baseline hot flush status on the responses of 
biochemical CVD surrogate markers to HT. My data demonstrate that hot flush status at 
baseline did not significantly affect the responses of various biochemical markers for CVD 
to HT, although the majority of markers (70%) showed a tendency towards more beneficial 
vascular responses in women with intolerable hot flushes (Study VI). As regards the overall 
effect of various forms of HT, my data are in line with most previous data; oral estradiol is 
accompanied by more pronounced beneficial changes in lipid and lipoprotein levels than 






with transdermal treatment (Tikkanen 1996a, Tikkanen 1996b, Godsland 2001, Kuhl 2005, 
Hemelaar et al. 2008).  In  my  study  the  most  pronounced  decreases  in  the  levels  of  total  
cholesterol were detected in connection with transdermal and oral estradiol, an outcome, 
however,  which  may  be  a  result  of  the  small  sample  size.  The  addition  of  MPA  to  oral  
estradiol  may  prevent  some  of  the  estradiol-induced  changes  in  biomarkers  due  to  its  
antiestrogenic properties (Sitruk-Ware 2004, Hermsmeyer et al. 2008);  such an effect of MPA 
was also seen in my study and most conspicuously in HDL, apoA-I and SHBG (Study VI).   
In recent years several re-analyses of HT trials have been made to evaluate the effect of hot 
flushes on the outcomes of HT. Re-analysis of the WHI data showed that the presence of 
moderate hot flushes at baseline was associated with a non-significantly lower risk of CVD 
in women aged 50–59 years (HR 0.86, 95% CI 0.44–1.65) (Rossouw et al. 2007). Interestingly, 
data regarding the effects of HT in older women with hot flushes are more divergent. In the 
WHI study women aged 70–79 years with moderate to severe hot flushes at the initiation of 
HT, had an increased risk of CHD associated with HT use (HR 5.08, 95% CI 2.08–12.40) 
(Rossouw et al 2007). Furthermore, re-analyses of the HERS (Huang et al. 2009) and Rancho 
Bernardo (Svartberg et al. 2009) studies  showed  that  in  women  over  65  years  of  age,  hot  
flushes at baseline seem to be associated either with an increased risk of CHD during the 
first  year  of  HT use  (HERS;  HR 9.01, 95% CI 1.15–70.35) or a lower all-cause mortality 
rate (Rancho Bernardo; HR 0.72, 95% CI 0.55–0.94), respectively. This diversity in results is 
interesting and warrants further research, since these trials were initially not designed to 
assess the impact of hot flushes, and the analyses were made retrospectively, when data on 
the influence of hot flushes had accumulated.  
 
Future directions for research include a need to assess the impact of hot flushes on glucose-
insulin balance. Large, prospective studies are needed to confirm the impact of hot flushes 
on outcomes of HT, and in future trials hot flush status should be considered a potential  
confounding factor. Furthermore, research should be directed to women with established 
cardiovascular risk factors at baseline, such as mild hypertension, smoking or 
hypercholesterolemia. Research should also be focused on older women in their 60s and 70s 













In conclusion, HT is the most effective treatment for hot flushes. Healthy, recently 
postmenopausal women with moderate to severe hot flushes should be given the 
opportunity to use estrogen alone (if hysterectomized) or in combination with an 
appropriate progestagen (if with intact uterus) to alleviate hot flushes and other symptoms. 
Possible contraindications for HT should be noted and cardiovascular risk factors should be 
evaluated and, if detected, treated accordingly; this particularly concerns elevated BP (Collins 
et al. 2007, Utian et al. 2008, International Menopause Society Consensus Statement 2009). My data 
show that the use of oral estradiol may present a risk of vasoconstriction and an increase of 
BP, but only in women with tolerable hot flushes. Luckily, in clinical practice today such 
women are seldom prescribed HT. However, if  HT is needed for women with no or only 











The present studies conducted on healthy, recently postmenopausal women allow the 
following conclusions: 
 
I Vasodilatory reactivity in women with severe hot flushes is greater than 
that in women with no, mild, or moderate hot flushes. Thus, vasomotor hot flushes could 
serve as marker of good vascular function. 
 
II Hot flushes of different degrees of severity are not associated with BP or 
heart rate except at night, when severe hot flush episodes are followed by transient rises in 
BP and heart rate. 
 
III Hot  flushes  of  different  degrees  of  severity  are  not  associated  with  
variation in the circulating concentrations of lipids, lipoproteins, SHBG or hs-CRP.  
 
IV The  use  of  oral  estradiol  alone  was  accompanied  by  a  vasoconstrictive  
response in women with tolerable hot flushes, whereas no such effect was detected in 
women with intolerable hot flushes or with the other treatment regimens. 
 
V Women with tolerable hot flushes responded to oral estradiol with 
elevations in both 24-hour and daytime systolic and diastolic BP. In contrast, use of 
transdermal estradiol resulted in decreases n 24-h and daytime BPs. In women with 
intolerable hot flushes decreases in BP were seen in connection with all treatment regimens. 
 
VI The responses of circulating concentrations of lipids, lipoproteins, SHBG 
and hs-CRP to oral and transdermal estradiol, the former with or without MPA, were 
comparable in women with tolerable and intolerable hot flushes. However, women with 
intolerable hot flushes responded with beneficial changes in 70% of the markers.  
 
The data demonstrate that hot flushes may affect various aspects of vascular function 
differently. Furthermore, they may clarify in part the conflict between the results of 
observational and randomized hormone studies. If HT is used for indications other than the 
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